

Korea's IVI signs strategic partnership with Hilleman Laboratories to advance vaccine & biologics development

May 5, 2026 | News

Strengthening global capacity to respond to current and future disease threats



The International Vaccine Institute (IVI) and Hilleman Laboratories have entered into a strategic partnership to collaborate on vaccines and biologics addressing global public health needs.

Bringing together two leading product development partnerships headquartered in Asia, this partnership aims to accelerate the development of life-saving solutions and strengthen global capacity to respond to current and future disease threats, particularly in underserved regions.

Under the Strategic Partnership Agreement, the organisations—headquartered in Seoul, Republic of Korea, and Singapore, respectively—will leverage complementary expertise to jointly design and implement projects spanning early research through clinical development, advancing candidates toward technology transfer, manufacturing, and broader access.

Dr Jerome H. Kim, Director General of IVI, said, “This strategic partnership with Hilleman Laboratories reflects our shared commitment to advancing vaccines and biologics that address pressing global health challenges, the strategic complementarity of our capabilities, and the substantial alignment of our visions for Global Health. By combining our expertise and networks, we can accelerate innovation and help ensure that life-saving interventions reach those who need them most.”

Raman Rao, Chief Executive Officer of Hilleman Laboratories, said, “This agreement envisions a more integrated path from early research into clinical development, bolstered by IVI’s global clinical and public health capabilities and Hilleman’s strengths in product development and technology transfer. Our intent is to advance candidates toward scalable manufacturing pathways, and ultimately enable wider access to these innovations, especially in low- and middle-income countries.”